Cargando…

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition

OBJECTIVE: Sodium–glucose cotransporter 2 (SGLT2) inhibitors cause substantially less weight loss than expected from the energy excreted via glycosuria. Our aim was to analyze this phenomenon quantitatively. RESEARCH DESIGN AND METHODS: Eighty-six patients with type 2 diabetes (HbA(1c) 7.8 ± 0.8% [6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrannini, Giulia, Hach, Thomas, Crowe, Susanne, Sanghvi, Arjun, Hall, Kevin D., Ferrannini, Ele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2015
Materias:	Emerging Technologies and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542276/ https://www.ncbi.nlm.nih.gov/pubmed/26180105 http://dx.doi.org/10.2337/dc15-0355

Ejemplares similares

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
por: Ferrannini, Ele, et al.
Publicado: (2020)

Performance of the Medtronic Sentrino continuous glucose management (CGM) system in the cardiac intensive care unit
por: Kosiborod, Mikhail, et al.
Publicado: (2014)

Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp
por: Ly, Trang T., et al.
Publicado: (2014)

Performance of the FreeStyle Libre Flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus
por: Fokkert, M J, et al.
Publicado: (2017)

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
por: Ghazi, Tara, et al.
Publicado: (2014)

Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
por: Sherr, Jennifer L., et al.
Publicado: (2014)

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
por: Polidori, David, et al.
Publicado: (2014)

Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms
por: Riddy, Darren M, et al.
Publicado: (2021)

Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes
por: Morgantini, Cecilia, et al.
Publicado: (2011)

Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes
por: Trujillo, Jennifer M., et al.
Publicado: (2017)

Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus
por: Chino, Yukihiro, et al.
Publicado: (2021)

Impact of Ramadan fasting on glucose levels in women with gestational diabetes mellitus treated with diet alone or diet plus metformin: a continuous glucose monitoring study
por: Afandi, Bachar O, et al.
Publicado: (2017)

Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial
por: Wada, Eri, et al.
Publicado: (2020)

Strains of Faecalibacterium prausnitzii and its extracts reduce blood glucose levels, percent HbA1c, and improve glucose tolerance without causing hypoglycemic side effects in diabetic and prediabetic mice
por: Kallassy, John, et al.
Publicado: (2023)

Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline
por: Pratley, Richard E, et al.
Publicado: (2022)

Restoring Insulin Secretion (RISE): Design of Studies of β-Cell Preservation in Prediabetes and Early Type 2 Diabetes Across the Life Span
Publicado: (2014)

Enhancement of Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
por: Novak, Vera, et al.
Publicado: (2014)

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014)

B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
por: Pescovitz, Mark D., et al.
Publicado: (2014)

Internet-delivered cognitive behaviour therapy for depression in people with diabetes: study protocol for a randomised controlled trial
por: Robins, Lisa, et al.
Publicado: (2015)

Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength
por: Elleri, Daniela, et al.
Publicado: (2014)

Vitamin D for the treatment of painful diabetic neuropathy
por: Basit, Abdul, et al.
Publicado: (2016)

Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes
por: Demeester, Simke, et al.
Publicado: (2015)

Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study
por: Skyler, Jay S., et al.
Publicado: (2015)

Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes
por: Belfort-DeAguiar, Renata D., et al.
Publicado: (2015)

Rationale and Design of the Vitamin D and Type 2 Diabetes (D2d) Study: A Diabetes Prevention Trial
por: Pittas, Anastassios G., et al.
Publicado: (2014)

Metabolic Effects of Exercise Training Among Fitness-Nonresponsive Patients With Type 2 Diabetes: The HART-D Study
por: Pandey, Ambarish, et al.
Publicado: (2015)

Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System
por: Castle, Jessica R., et al.
Publicado: (2015)

Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin
por: Levin, Philip A, et al.
Publicado: (2016)

Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study
por: Wieringa, Thomas H, et al.
Publicado: (2018)

Identification of Unique Antigenic Determinants in the Amino Terminus of IA-2 (ICA512) in Childhood and Adult Autoimmune Diabetes: New Biomarker Development
por: Acevedo-Calado, Maria, et al.
Publicado: (2017)

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
por: Gomez-Peralta, Fernando, et al.
Publicado: (2020)

Multilevel clustering approach driven by continuous glucose monitoring data for further classification of type 2 diabetes
por: Tao, Rui, et al.
Publicado: (2021)

Non-invasive wearables for remote monitoring of HbA1c and glucose variability: proof of concept
por: Bent, Brinnae, et al.
Publicado: (2021)

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
por: Chow, Elaine, et al.
Publicado: (2023)

Diabetes patient preferences for glucose-monitoring technologies: results from a discrete choice experiment in Poland and the Netherlands
por: Smith, Ian P, et al.
Publicado: (2023)

Response to Comment on: Ferrannini. Learning From Glycosuria. Diabetes 2011;60:695–696
por: Ferrannini, Ele
Publicado: (2011)

Learning From Glycosuria
por: Ferrannini, Ele
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8934nk72m661tqm7enso93iv5d